Early trial tests new pill for Tough-to-Treat blood cancer
NCT ID NCT03760523
Summary
This early-stage study aimed to find a safe and effective dose of an experimental oral drug called Minnelide for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatments. The trial enrolled 27 participants to determine the highest dose they could tolerate without severe side effects. The goal was to gather initial safety data and identify a recommended dose for future testing, as this was the first time the drug was being given to people with this type of leukemia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.